About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.

Our first novel microbiome modulator, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.

picture
  • Discovering a new frontier in digestive health
  • Linking changes in the microbiome with therapeutic benefit

Learn More

picture
  • A breakthrough treatment aiming to eradicate symptoms of lactose intolerance
  • Potential to become the first FDA-approved product to treat lactose intolerance
  • Studied in Phase 2 trial

About RP-G38

Latest News
Latest News
Latest News

Featuring Recent Posts WordPress Widget development by YD